Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 78, Issue 1, Pages 195-211
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-03-16
DOI
10.1097/hep.0000000000000351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis
- (2022) Grazia Pennisi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
- (2022) Arun J. Sanyal et al. JOURNAL OF HEPATOLOGY
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
- (2021) Ferenc Emil Mózes et al. GUT
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis
- (2021) Emmanuel Anandraj Selvaraj et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
- (2021) Annalisa Berzigotti et al. JOURNAL OF HEPATOLOGY
- Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database
- (2021) Alessandro Vitale et al. GUT
- MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
- (2021) Mazen Noureddin et al. JOURNAL OF HEPATOLOGY
- Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
- (2020) Philip N Newsome et al. Lancet Gastroenterology & Hepatology
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
- (2020) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
- (2020) Alessandro Mantovani et al. GUT
- A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis
- (2020) Andrea Dennis et al. Scientific Reports
- MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis
- (2020) Jinho Jung et al. GUT
- Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Salvatore Petta et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
- (2019) Fernando Bril et al. DIABETES CARE
- Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non‐alcoholic Fatty Liver Disease
- (2019) Fasiha Kanwal et al. HEPATOLOGY
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH
- (2018) J. Boursier et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity
- (2018) Geraldine J. Ooi et al. INTERNATIONAL JOURNAL OF OBESITY
- Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients
- (2018) Harshit Garg et al. Surgery for Obesity and Related Diseases
- Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease
- (2016) Akira Okajima et al. HEPATOLOGY RESEARCH
- Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease
- (2016) Kojiro Seki et al. HEPATOLOGY RESEARCH
- Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
- (2010) S. McPherson et al. GUT
- Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis
- (2010) Zhong-Hua Lin et al. HEPATOLOGY
- Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis
- (2009) Marianne Ziol et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
- (2009) Vincent Wai-Sun Wong et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now